Vetter has added a third cleanroom as part of an expansion of its US early-stage development site at the Illinois Science and Technology Park in suburban Chicago.
Vetter, a CDMO specializing in aseptic filling, announced that it has added a third cleanroom as part of an expansion of its US early-stage development site at the Illinois Science and Technology Park in suburban Chicago.
The overall 30,000-square-foot site has the capabilities needed for early-stage clinical manufacturing (i.e., preclinical to Phase II), including chemical analysis and microbiology labs, material preparation, and compounding functions. At the heart of the facility is its three cleanrooms, followed by visual inspection capabilities and GMP storage.
With the recent addition of the third cleanroom, filling of single-chamber syringes is now available with a maximum filling speed of 3,600 units per hour, and batch sizes as large as 25,000 units. The line is constructed as a restricted access barrier system (RABS), offering various filling pumps depending upon products unique characteristics, as well as fully automated tub processing. The two existing cleanrooms, both operational since late 2011, provide fully automated vial filling for batches up to 10,000 liquid or lyophilized vials, as well as semi-automated filling for manufacturing prefilled syringes, cartridges, and vials in small batch sizes of a few hundred.
The new cleanroom is similar to the one in Vetter’s European development operations in Ravensburg, Germany. With this expansion at the Chicago facility, customers can have access to an early drug development platform. By being able to realize the clinical manufacturing of prefilled vials, syringes, and cartridges in Chicago, bio/pharmaceutical companies will be able to utilize the final packaging material, depending upon the individual product characteristics, and planned launch strategy already in the early development phases.
Source: Vetter
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.